VSTM

Verastem, Inc. (VSTM) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Verastem, Inc. is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its primary commercial product is AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib), FDA-approved in May 2025 for recurrent low-grade serous ovarian cancer (LGSOC). The company is also advancing its pipeline, including the KRAS G12D inhibitor VS-7375.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $18.7 million in product revenue in Q1 2026, compared to zero in Q1 2025, following the May 2025 FDA approval and commercial launch of AVMAPKI FAKZYNJA CO-PACK.
• Expense Growth: Total operating expenses increased 44% year-over-year. R&D expenses rose 31% ($9.1 million) driven by increased clinical trial costs for the VS-7375 program and LGSOC studies. SG&A expenses rose 48% ($7.3 million) due to commercialization build-out and personnel costs.
• Net Loss Improvement: Net loss decreased by $15.5 million (30%) year-over-year. This improvement was significantly aided by a $9.3 million gain from the change in fair value of warrant liability (due to warrant exercises and expiration) and the absence of a $1.8 million loss on debt extinguishment recorded in Q1 2025.
• Liquidity: Cash and investments increased to $181.7 million, bolstered by $29.4 million in proceeds from warrant exercises in Q1 2026.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has disclosed that conditions raise substantial doubt about the company's ability to continue as a going concern for twelve months following the issuance of these financial statements. This is due to the initiation of three new Phase 2 registration-directed trials (TARGET-D 201, 202, 203) for VS-7375, which significantly increased projected R&D expenses beyond the cash resources available as of the 10-K filing date.
• Financing Needs: The company expects to fund operations through existing cash, future product revenues, potential milestones from the Secura Bio agreement, and the Note Purchase Agreement. However, additional financing (equity, debt, or collaborations) may be required.
• Clinical Updates:
  • AVMAPKI FAKZYNJA: New two-year median follow-up data from the RAMP 201 trial demonstrated durable benefit in both KRAS-mutant and wild-type LGSOC patients.
  • VS-7375: The company initiated three Phase 2 registration-directed trials for pancreatic, lung, and colorectal cancers. The partner GenFleet received Breakthrough Therapy Designation in China for VS-7375 (GFH375) in pancreatic and lung cancer indications.
• Debt Structure: The company has a $75.0 million Note Purchase Agreement with a floating interest rate and revenue participation payments. The fair value of these notes is recorded at $73.1 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $181.7 million cash balance against the newly committed costs for the three VS-7375 Phase 2 trials and ongoing commercialization of AVMAPKI FAKZYNJA.
• Revenue Sustainability: Assess the durability of the $18.7 million quarterly revenue run rate and the impact of payer rebates and discounts on net revenue.
• Debt Covenants: Review the terms of the Note Purchase Agreement, specifically the revenue participation percentage (1.0% currently, up to 2.0%) and the conditions for the "Second Purchase" and "Third Sale" tranches.
• Going Concern Mitigation: Monitor for announcements regarding new financing, strategic partnerships, or cost-cutting measures to address the substantial doubt disclosure.
• Warrant Liability: Note that all public warrants from the July 2024 offering were exercised or expired in Q1 2026, eliminating this specific liability but increasing share count (8.4 million shares issued upon exercise).